no implicated drug, the patient was excluded. Yet in the list of drugs contributing to death the authors mention that a number of drug details were not available. These statements are contradictory. It is difficult to understand how the researchers were able to reconcile the diagnosis of DILI when the ingredients are unknown in such a large number of patients. From a total of 27,245 cases, the authors state 25,927 had a probable or highly probable DILI. This means an astonishing 95.2% were at least probable on a retrospective analysis with no predefined criteria for DILI.
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RE: Incidence and Etiology of Drug-Induced Liver Injury in Mainland China
Dear Editors:
We read with interest the recent article published in Gastroenterology by Shen et al, 1 which reported findings of a retrospective study that determined the incidence and causes of drug-induced liver injury (DILI) in mainland China, and the leading cause of DILI was traditional Chinese medicines (TCM) or herbal and dietary supplements (HDS; 26.81%). Although this is the first large-scale estimate of DILI incidence and etiology in mainland China, there remain several critical issues inevitably making its conclusions to be reconsidered.
One of our major concerns with this analysis is that the implicated drug categories adopted in this study might seriously influence the reliability of conclusions. The authors separated conventional drugs into several categories according to the therapeutic aims or pharmacological types, which is a kind of well-acknowledged way, to compare the proportion of each category. However, the authors failed to separate TCM and HDS into corresponding categories to have an equal comparison with conventional drugs, which caused the apparently highest percentage of TCM and HDS versus the other drug categories. TCM drugs used in China have >8,000 patent drugs and numerous prescription formulas by TCM physicians, which are comparable to the numbers of conventional drugs. Thus, to combine all the TCM drugs into 1 category is not reasonable when comparing the proportions of drug categories. If we combine all the conventional drugs into 1 category, it is obvious that conventional drugs contributed remarkable larger proportion of DILI cases than that of TCM and HDS (73.19% vs 26.81%). Thus, it can be seen TCM and HDS are not the most contributor of DILI in mainland China, which led to a completely different conclusion from that of this article.
Notably, the authors separate the antituberculosis drugs (tuberculostatics) from the anti-infectious drugs when comparing drugs. This is not a wrong point, but it caused the significant decrease of proportion of the anti-infectious drugs (6.08% in this study). If the antituberculosis drugs were integrated into anti-infectious category, the latter will reach the highest proportion (28.07%) of DILI in mainland China, even though TCM and HDS were combined as one category (26.81%). This is tricky to extract the subcategories of drugs-antituberculosis ones-from the antiinfectious category and thus to present an apparently highest proportion of TCM and HDS.
Our second concern is that the method for DILI diagnosis adopted in this study is not proper for TCM-induced DILI.
Owing to the lack of clear diagnostic indicators, an exclusion diagnosis of DILI is commonly used clinically, but reports from Europe and America indicated that the misdiagnosis rate of DILI reached 47.1% and 28.5%, respectively. [2] [3] [4] Although the Roussel Uclaf Causality Assessment Method (RUCAM) is widely documented in literature for DILI, some ambiguous questions and weaknesses influence its accuracy resulting in an update in 2015. RUCAM is more limited in assessing the causality of TCM owing to fewer warning labels and published reports regarding the hepatotoxicity and frequent polypharmacy of TCM. 2 Moreover, the quality variation, adulteration, and toxin contaminants of TCM are not included in the RUCAM system. Additionally, clinical diagnosis of TCM DILI is more difficult because of the complicated compositions of formula, drug combination, misuse and unreasonable use, physique, heredity, and so on. Misuse and unreasonable use are in a large proportion in practice. For example, the radix of Gynura segetum (Lour.) Merr (Tu-San-Qi in Chinese) is a completely misused substitute and fake substitution for Panax notoginseng (Burkill) F. H. Chen (San-Qi in Chinese). Tu-San-Qi is not stipulated in Chinese Pharmacopoeia as TCM.
In summary, we suggest interpreting this study by Shen at al as a beneficial attempt in researching TCM DILI and herbinduced liver injury (HILI), which is far from a final adjudication. HILI has become a global concern due to the widespread use of products containing herbs. Fortunately, steps forward have been taken. In 2016 and 2018, the China Association of Chinese Medicine and the China Food and Drug Administration (the predecessor of National Medical Product Administration) issued Guidelines for clinical diagnosis of herb-induced liver injury and Guidance for the clinical evaluation of traditional Chinese medicine-induced liver injury respectively, developing an organized and systemic approach to HILI. [5] [6] [7] [8] However, it must be made clear that such guideline should be continuously revised and improved in accordance with research progress and regulatory requirements.
WEIHONG CONG QIQI XIN Xiyuan Hospital China Academy of Chinese Medical Sciences Beijing, China

YUEQIU GAO Shuguang Hospital Shanghai University of Traditional Chinese Medicine Shanghai, China
Reply. We have carefully read the letters from our peers who are interested in our work, which we explain and discuss below. The diagnosis at discharge are all made as drug-induced liver injury (DILI) for the initially screened 29,478 patients. According to the protocol, all these cases needed to be reevaluated by the Roussel Uclaf causality assessment method (RUCAM) or expert opinion process, which was recognized as assessment of causality, to confirm that they were probable or highly probable DILI cases. There were 25,927 patients who were finally confirmed to be in accordance with the protocol and enrolled into the study. 1 Therefore, the term "confirmed DILI cases" described in the abstract referred to the probable or highly probable DILI cases, which were confirmed by the reevaluation process. This was also the reason why the study had a high screening success rate.
According to the European DILI guideline released this year, liver biochemical threshold should meet one of the following criteria: (1) alanine aminotransferase of !5Â the upper limit of normal (ULN); (2) alkaline phosphatase of !2Â ULN; and (3) alanine aminotransferase of !3Â ULN þ total bilirubin (TBIL) of !2Â ULN. 2 However, in our study, inclusion criteria did not include specific cutoff levels for liver chemistries. The reason is that Chinese DILI guideline (issued in 2015 in Chinese version) emphasizes on causality assessment, without specifically recommending the liver biochemical threshold when diagnosing DILI. 3 Therefore, it was inevitable that some of the mild DILI cases who might be considered as an adaptor were included. It should be noted that among the 25,927 enrolled cases in this study, 23.38% of patients had preexisting liver diseases, and were all assessed as probable or highly probable DILI at liver injury onset.
Information regarding the suspected drugs was determined according to the medical history records. Cases who had no drug information or whose causality was unable to assess owing to incomplete drug information were excluded from the study. As a large-scale retrospective study, some of the suspected drug information was not comprehensive. "Details unknown" of the drug described in the article was referring to the missing of detailed chemical/trade name of the drug; however, the information of the class of the drug were well-recorded in the medical history.
The DILI-associated mortality rate in this study was lower than we expected, as mentioned by our peers. One possible reason is that some of the patients had mild disease, which would usually be excluded in other registries. The other reason is that, the inpatients that we screened were not only hospitalized for liver disease, most of these cases came from other departments. In the study of Chen's team (fatality rate of 8.6%), all DILI cases were from department of liver disease, whose liver injury might be more severe. 4 
